The State of the Union in Cancer Innovation
PM360
JULY 13, 2023
Our clinical data is encouraging and supports potential registrational paths based upon its molecular design focused upon selectivity for cancer-relevant T cells and decreased side effects. What Is Your Company Currently Working On? Preliminary data are expected in 2023.
Let's personalize your content